MGMT and central nervous system cancer: Of interest, mean number of methylated CpG sites in glioblastoma as well as IDHwt astrocytoma with pTERTmut were comparable to mean number of methylated CpG sites in a cohort of glioma WHO grade II recently described by our group [8], suggesting extent of MGMT promotor methylation to be independent of histopathological WHO grade and may rather depend on molecular markers.